These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 10397748)

  • 1. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia.
    Larson RA; Wang Y; Banerjee M; Wiemels J; Hartford C; Le Beau MM; Smith MT
    Blood; 1999 Jul; 94(2):803-7. PubMed ID: 10397748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children.
    Smith MT; Wang Y; Skibola CF; Slater DJ; Lo Nigro L; Nowell PC; Lange BJ; Felix CA
    Blood; 2002 Dec; 100(13):4590-3. PubMed ID: 12393620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis.
    Christiansen DH; Andersen MK; Pedersen-Bjergaard J
    J Clin Oncol; 2001 Mar; 19(5):1405-13. PubMed ID: 11230485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NAD(P)H:quinone oxidoreductase 1 null genotype is not associated with pediatric de novo acute leukemia.
    Sirma S; Agaoglu L; Yildiz I; Cayli D; Horgusluoglu E; Anak S; Yuksel L; Unuvar A; Celkan T; Apak H; Karakas Z; Devecioglu O; Ozbek U
    Pediatr Blood Cancer; 2004 Oct; 43(5):568-70. PubMed ID: 15382274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia.
    Pedersen-Bjergaard J; Pedersen M; Roulston D; Philip P
    Blood; 1995 Nov; 86(9):3542-52. PubMed ID: 7579462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS.
    Fern L; Pallis M; Ian Carter G; Seedhouse C; Russell N; Byrne J
    Br J Haematol; 2004 Jul; 126(1):63-71. PubMed ID: 15198733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
    Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
    Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia.
    Bolufer P; Collado M; Barragan E; Calasanz MJ; Colomer D; Tormo M; González M; Brunet S; Batlle M; Cervera J; Sanz MA
    Br J Haematol; 2007 Feb; 136(4):590-6. PubMed ID: 17367411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults.
    Smith MT; Wang Y; Kane E; Rollinson S; Wiemels JL; Roman E; Roddam P; Cartwright R; Morgan G
    Blood; 2001 Mar; 97(5):1422-6. PubMed ID: 11222389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The frequencies of NAD(P)H quinone oxidoreductase (NQO1) variant allele in Israeli ethnic groups and the relationship of NQO1*2 to adult acute myeloid leukemia in Israeli patients.
    Malik E; Cohen SB; Sahar D; Dann EJ; Rund D
    Haematologica; 2006 Jul; 91(7):956-9. PubMed ID: 16818284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inversion of chromosome 16 and uncommon rearrangements of the CBFB and MYH11 genes in therapy-related acute myeloid leukemia: rare events related to DNA-topoisomerase II inhibitors?
    Dissing M; Le Beau MM; Pedersen-Bjergaard J
    J Clin Oncol; 1998 May; 16(5):1890-6. PubMed ID: 9586906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence of biallelic point mutations in the Runt domain of the AML1/PEBP2 alpha B gene in Mo acute myeloid leukemia and in myeloid malignancies with acquired trisomy 21.
    Preudhomme C; Warot-Loze D; Roumier C; Grardel-Duflos N; Garand R; Lai JL; Dastugue N; Macintyre E; Denis C; Bauters F; Kerckaert JP; Cosson A; Fenaux P
    Blood; 2000 Oct; 96(8):2862-9. PubMed ID: 11023523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.
    Blanco JG; Edick MJ; Hancock ML; Winick NJ; Dervieux T; Amylon MD; Bash RO; Behm FG; Camitta BM; Pui CH; Raimondi SC; Relling MV
    Pharmacogenetics; 2002 Nov; 12(8):605-11. PubMed ID: 12439220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High frequency of NAD(P)H:quinone oxidoreductase 1 (NQO1) C(609)T germline polymorphism in MDS/AML with trisomy 8.
    Zachaki S; Stavropoulou C; Koromila T; Manola KN; Kalomoiraki M; Daraki A; Koumbi D; Athanasiadou A; Kanavakis E; Kollia P; Sambani C
    Leuk Res; 2013 Jul; 37(7):742-6. PubMed ID: 23643325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements.
    Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J
    Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II.
    Super HJ; McCabe NR; Thirman MJ; Larson RA; Le Beau MM; Pedersen-Bjergaard J; Philip P; Diaz MO; Rowley JD
    Blood; 1993 Dec; 82(12):3705-11. PubMed ID: 8260707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. dic(5;17): a recurring abnormality in malignant myeloid disorders associated with mutations of TP53.
    Wang P; Spielberger RT; Thangavelu M; Zhao N; Davis EM; Iannantuoni K; Larson RA; Le Beau MM
    Genes Chromosomes Cancer; 1997 Nov; 20(3):282-91. PubMed ID: 9365836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and susceptibility to therapy-related myeloid neoplasms.
    Leone G; Fianchi L; Pagano L; Voso MT
    Chem Biol Interact; 2010 Mar; 184(1-2):39-45. PubMed ID: 20026017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lung cancer in Mexican-Americans and African-Americans is associated with the wild-type genotype of the NAD(P)H: quinone oxidoreductase polymorphism.
    Wiencke JK; Spitz MR; McMillan A; Kelsey KT
    Cancer Epidemiol Biomarkers Prev; 1997 Feb; 6(2):87-92. PubMed ID: 9037558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NAD(P)H:quinone oxidoreductase (NQO1) polymorphism, exposure to benzene, and predisposition to disease: a HuGE review.
    Nebert DW; Roe AL; Vandale SE; Bingham E; Oakley GG
    Genet Med; 2002; 4(2):62-70. PubMed ID: 11882782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.